Advancing Biomarker Discovery, Computational Models & Combination Strategies to Optimize Precision Therapy Efficacy & Safety for Greater Response Rates in IBD Patients
Faced with persistently low response rates and significant patient heterogeneity, the IBD community is doubling down on precision medicine approaches. From leveraging microbiome data and AI for patient stratification, to developing novel biomarkers and next generation multi-omic approaches, drug developers are working to improve treatment selection and increase response rates for patients with Crohn's Disease and Ulcerative Colitis.
However, despite the emergence of new innovations and technologies for precision approaches, the challenge remains in translating them into clinically validated strategies that meaningfully improve patient outcomes. That's why the community is gathering at the 5th Precision Medicine in Inflammatory Bowel Disease Summit, the industry's only dedicated forum for advancing translational development, optimizing clinical trial design, refining patient stratification, and accelerating biomarker development to move beyond the "one-size-fits-all" approach and ensure the right drug reaches the right patients.
Join 60+ leaders across inflammation, immunology, and precision medicine from the likes of Xencor, AbbVie, Merck, Mirador Therapeutics, Takeda, and more for 3 days of data-driven insights and dedicated networking opportunities. Connect with like-minded peers committed to transforming IBD treatment through better biomarkers, smarter clinical development, and truly personalized care.
I enjoyed the topics and the speakers, which cover innovations about how to use AI for markers development, and other hot topics in Precision Medicine in IBD. Long networking times, made us really understand each other and discuss more deeply for interesting topics
3rd Precision Medicine in IBD Summit 2025 Attendee, AbbVie
It was an informative and stimulating meeting in an intimate setting. I liked the small size of the meeting. There were a lot of opportunities to network and meet other attendees, and the talks were high quality
4th Precision Medicine in IBD Summit 2026 Attendee, Mirador Therapeutics
I’m looking forward to learning about the progress of Precision Medicine in the IBD field, and exchanging ideas about novel approaches
Joerg Heyer, Head of Translational Science and Medicine, Palisade Bio
Here’s what you can expect in 2027:
Explore the 2027 Full Event Guide
- DISCOVER how biopharma is moving beyond ‘trial and error’ treatment approaches
- SHAPE your patient stratification strategies with predictive biomarker advances
- BUILD your understanding of the multi-omic, spatial-omics and AI-driven technologies
- LEARN how IBD is taking notes from oncology endpoints, to transform trial design
- CONNECT with 60+ leader of the Precision Medicine community across IBD drug development
2027 Speakers
Attending Companies Include
Explore Related Events
Explore the Agenda
Discover exactly how leading teams are tackling challenges from combination therapies to AI-driven biomarker discovery, to see how your program can benefit.
Partner With Us
Position your solutions in front of decision-makers actively looking for support with their precision medicine approaches, and become a trusted partner worldwide.
Join IBD Leaders
Connect with the IBD community striving to stratify patients, through predictive biomarkers and better understanding of disease mechanism.